Pharmamar

PM060184 is a new marine-derived compound which has shown strong antitumor activity in preclinical models and a favorable safety profile in animal toxicology studies

PharmaMar Initiates a Phase III Registration Trial with Aplidin(R) in Multiple Myeloma Patients

MADRID, February 8, 2011 - PharmaMar SA (Grupo Zeltia, ZEL.MC) has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors.

MORE..

Older News

MADRID, June 8, 2010 - PharmaMar SA (Grupo Zeltia, ZEL.MC) today announced that a registration trial in relapsed/refractory multiple myeloma patients has been initiated with Aplidin(R) (plitidepsin) in combination with dexamethasone versus dexamethasone alone.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy